A B S T R A C T Human coagulation
INTRODUCTION
Human Factor VII is a single chain, vitamin K-dependent serine protease present in plasma that can be converted to a two-chain form, Factor VIla, by a number of agents including thrombin, Factor Xa, and Factor XIIa (1) . This conversion is associated with a >24-40-fold increase in activity when measured in a onestage coagulation assay (1) (2) (3) .
Tissue factor is a lipoprotein cofactor that markedly enhances the proteolytic activity of Factors VII and VIIa upon Factors IX and X (4, 5) . The activation of Factor X to Factor Xa by tissue factor and Factor VII or VIla constitutes the classical "extrinsic" pathway of coagulation (6) .
Tissue factor has been detected in many tissues and cultured cells including human fibroblasts (7, 8) and smooth muscle cells (9) . Blood cells, however, lack significant tissue factor activity unless they are stimulated
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Received for publication 9 March 1982 and in revised form 28 April 1982. by a variety of agents-for example, endotoxin (10) , immune complexes (11) , or complement C5a (12) . Although granulocytes or lymphocytes were initially felt to produce this tissue factor activity, more recent studies have established the monocyte as its source (13) (14) (15) .
In most studies of production of tissue factor by monocytes, total activity is measured following disruption of the cells by freeze-thawing or sonication. However, at least a portion of the tissue factor activity has been found to be available on whole, intact cells following their stimulation. By analogy with the reported binding of Factor Xa to platelets (16) through its cofactor, Factor Va, it appeared possible that Factor VII or VIla bind to tissue factor at the monocyte surface and there activate Factor X (and Factor IX).
Single chain, zymogen, Factor VII is unique among the vitamin K-dependent proteases in that it appears to contain inherent coagulation activity. Recently, Nemerson et al. (17) have presented a cogent, albeit indirect, argument for this fact using bovine Factor VII and VIla. Further, using a kinetic system involving the activation of Factor IX, they have shown that Factor VII and Factor VIla have similar, if not identical, affinities for purified tissue factor.
We now show that human Factor VII and VIla bind to the surface of stimulated, intact monocytes with essentially the same affinities and furthermore, that the binding of Factor VII or VIIa to monocytes is associated with the proteolytic activation of Factor X. (18) , resuspended in 300 ml of cold PBS/EDTA and centrifuged at 500 g in a Beckman J6-B centrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA) for 10 min. The cell pellets were resuspended in 50 ml cold PBS/HSA/EDTA and washed again by centrifugation. This pellet was resuspended in 100 ml of PBS/HSA/EDTA and placed on ice for elutriation.
METHODS
Countercurrent elutriation was performed using a Beckman J21-B high-speed centrifuge equipped with a JE-6 elutriator rotor and strobe unit. A Cole-Parmer model 7013 Masterflex pump (Cole-Parmer Instrument Co., Chicago, IL) was used to control flow through the system which was monitored by a flow meter (model B-5684, Roger Gilmont Instruments, Inc., Great Neck, NY). Before each procedure, the entire system was washed extensively with ethyl alcohol (95%), followed by sterile water, and finally cold PBS/HSA/ EDTA. The centrifuge was kept at 4°C and 400 g throughout.
By adjusting flow rates appropriately, lymphocytes and monocytes can be obtained using this elutriation system (19, 20) . For the studies reported here, however, the goal was purification of monocytes alone, and an abbreviated elutriation schedule was used. The cell sample was loaded into the elutriation chamber at a flow rate of 9.4 ml/min, followed by 250 ml of PBS/HSA/EDTA at 9.4-10.5 ml/min, and finally 150 ml of buffer at 16 Identification of cells. Cells were identified by morphology and, initially, nonspecific esterase staining (alpha naphthylbutyrate or Sigma Histozyme kit 90-Al). Subsequently, neutral red was used, as it was faster, more convenient, and gave results very comparable (±2%) to nonspecific esterase staining (21, 22) . 200 cells or more were examined to obtain a differential count.
LPS. LPS was a phenol extract of Escherichia coli 026:B6 or 055:B5 (Sigma Chemical Co.). Following resuspension in 0.15 M NaCl at a concentration of 5 mg/ml, the suspension was sterilized by passage through a 0.45-,um filter and stored at 4°C. The concentration of LPS in the stock suspension was assumed to remain 5 mg/ml following filtration. The concentrations of LPS added to the cultures were chosen to stimulate maximal monocyte tissue factor production ,ug/ml).
Proteins. Factor VII was purified using a modification of a previously published method (3). Its molecular weight was assumed to be 48,000 (1) and an extinction coefficient (A,,cm at 280 nm) of 11.5 was estimated by the method of Babul and Stellwagen (23) .
Factor X was purified essentially as previously described (24) . Bovine Factor XIIa was a gift from Dr. K. Karachi and Dr. E. Davie (University of Washington, Seattle) and the Factor X coagulant protein from Russell's viper venom was a gift from K. Levine and Dr. C. Jackson (Washington University, St. Louis).
Crude human brain thromboplastin was prepared as previously described (1) .
Iodination of Factor VII. Factor VII was labeled with ['25I]iodide using a modification of the method of Fraker and Speck (25) . 10 A portion of the radiolabeled Factor VII was converted to two-chain Factor Vlla by incubation (100 ,ug/ml) with 2% (wt/wt) of bovine Factor XIIa in 0.15 M NaCl, 0.02 M Hepes, pH 7.4, with 1 mg/ml bovine serum albumin at 4°C for 48 h. The iodinated single-and two-chain proteins were stored at a concentration of 1 ug/ml in HRB at -70°C.
In four iodination procedures the specific activity of the labeled Factor VII or VIIa ranged from 17,600 to 26,400 dpm/ng. In each instance, >99.5% of the radioactivity was precipitated by 10% TCA. Functional, one-stage coagulation assays of Factor VII, pre-and immediately postiodination showed no change in activity (2 units/,ug±10%). Activation of labeled Factor VII to VIla was associated with a 28-fold increase in activity. When the proteins were stored at a concentration of 1 Mg/ml there was a gradual loss of functional activity, such that by 12 wk Factor VII had 50% and Factor VIla 20% of its original activity when compared with unlabeled standards. If the labeled proteins were stored at higher concentrations, inactivation occurred considerably more rapidly. For the experiments presented here, the iodinated Factor VII and VIla were used within 4 wk of the labeling procedure. Fig. 1 shows the activation of iodinated Factor VII to VIIa by Factor XIIa.
Binding assays. Although a centrifugation through oil technique, similar to that previously described for platelets (16) was initially planned to assay binding of Factor VII and VIIa to monocytes, it was found to be unsuitable. When these stimulated monocytes were spun through a mixture of Nbutyl phthalate/Apezion oil (9:1, density 1.028) it was evident both visually and by following specific radiolabeled Factor VII and VIIa binding that only a portion of the cells pelleted to the bottom of the tube as compared with cells centrifuged in the absence of oil. This problem was most marked at low monocyte concentrations (<2 X 106/ml) and could be corrected by the inclusion of 1-2 X 108/ml platelets (but not lymphocytes or erythrocytes). Therefore, the two-..,* .. ' FIGURE 1 Activation of radiolabeled Factor VII to VIIa by bovine Factor XIIa. Factor VII (100 ,g/ml) was activated with bovine Factor XIIa (2 .g/ml) in 0.15 M NaCl, 0.02 M Hepes, pH 7.4, with 1 mg/ml bovine serum albumin at 4°C. SDS-polyacrylamide gel electrophoresis and autoradiography was performed on samples either unreduced (lanes 1-5) or reduced with 5% ,3-mercaptoethanol (lanes 6-10), which were removed at 0, 6, 12, 24, and 48 h (left to right in figure).
step centrifugation procedure described below was used in all experiments.
200 Ml of monocytes (1 X 107/ml) were added to 12 X 75 mm-polystyrene tubes containing 300 pI of HRB, '25I-Factor VII or VIIa and CaCi2. Reaction mixtures routinely contained 4 mM CaC12 and various concentrations of '251-Factor VII or Vlla. The mixtures were incubated 60 min at 0°, 200, or 37°C and, following gentle resuspension, a 400-Al portion was transferred to 1.5-ml polypropylene tubes and centrifuged for 2 min in a microfuge (Brinkmann Instruments, Inc., Westbury, NY) at ambient temperature. There was no detectable loss of cell viability during the incubation procedure itself as determined by trypan blue exclusion. 800
Ml of N-butyl phthalate was layered over the sample and the tube was centrifuged an additional 2 min. A 200-Ml portion of the supernatant (now above the oil layer) was removed for determination of "free" Factor VII or VIIa and the remainder of the supernatant and N-butyl phthalate aspirated. The bottom of the tube containing the cell pellet was then cut off and counted for "bound" Factor VII or VIIa.
Nonspecific binding, as determined by the inclusion of 2.4
Mg/ml unlabeled Factor VII or Vlla in the reaction mixtures, was a constant fraction of total radioactivity added, and varied from 2.0 to 3.5%. Specific binding was assumed to be the difference between the observed and nonspecifically bound radioactivity. Radioactivity was counted on a Searle model 1190 gamma counter (Searle Radiographics, Inc., Des Plaines, IL) with a counting efficiency of 50%. Coagulation assays. One-stage coagulation assays for Factor X and Factor VII or Vlla were performed as previously described (1, 16) . To determine the rate of Factor X activation in the binding mixtures, a 200-Ml sample was removed, placed in a 12 X 75-mm polystyrene tube and 10
Ml of Factor X (final concentration 8 Mg/ml) was added. At 30-s intervals thereafter, 10-Ml samples were removed, diluted in 0.15 M NaCl, 0.02 M Tris, pH 7.5, 0.001 M EDTA, and 1 mg/ml bovine serum albumin (at least 50-fold) and assayed as previously described for Factor Xa activity (16) . A standard curve was constructed using Factor Xa produced from purified Factor X using 1% (wt/wt) Factor X coagulant protein from Russell's viper venom.
The tissue factor assay was performed in a fibrometer (Becton, Dickinson & Co., Rutherford, NJ) at 37°C. 60 Ml of Factor VIII-deficient plasma (George King Biomedical, Inc., Overland Park, KS), 60 MI of rabbit brain cephalin (1-9 dilution of stock suspension) and 60 Al of the sample to be assayed diluted appropriately in HRB with 0.005 M sodium citrate, were incubated 30 s at 37°C. The reaction was then started by addition of 60 Ml of 25 mM CaC12 at 37°C. A standard curve was constructed using crude human brain thromboplastin and gave a linear relationship between clotting times and thromboplastin dilution on a log-log plot. The activity of the stock human brain thromboplastin was arbitrarily given a value of 10,000 units/ml (a concentration of 200 units/ml in the assay gave a clotting time of 19.5 s and a concentration of 1 unit/ml, a clotting time of 96 s). The coagulant activity that developed in the monocytes following overnight incubation with LPS required Factor VII for expression.
To measure total tissue factor activity of the monocytes, the cells were lysed by sonication (15 Incubations of monocytes with radiolabeled Factor VII or VIIa were routinely performed at 0°C. This temperature was chosen to prevent further monocyte tissue factor production, inhibit possible confounding effects of cellular endocytosis, and inhibit adherance of the monocytes to the plastic test tubes (see below and Discussion).
Characteristics of Factor VII and VIIa binding to monocytes. Binding of Factor VII and VIIa to monocytes is time dependent, with maximal binding being obtained by 60 min, even at concentrations of Factor VII or VIIa as low as 0.4 ng/ml (data not shown). At 0°C the binding of zymogen, single-chain Factor VII to monocytes is very similar to that of activated, twochain Factor VIIa (Fig. 2) . That the binding observed using Factor VII was not due to its conversion to Factor VIIa during the incubation period itself was shown by SDS-polyacrylamide gel electrophoresis (under reducing conditions) and autoradiography of cell pellets during the time course experiment (Fig. 3) . Further, when the activation of Factor X to Xa was determined in samples containing Factor VII, a delay in Factor X activation was observed, which presumably represented the feedback activation of Factor VII by Factor Xa (Fig. 4) to Factor VIla during the 1-h incubation period. Whether this activation was related to a contaminating plasma protease, or one associated with the monocytes themselves, has not yet been determined. The binding of both '251-Factor VII and VIIa could be reversed by the addition of either unlabeled Factor VII or Factor VIIa or by the chelation of calcium with EDTA. Fig. 5 shows the effect of adding a 100-fold excess of unlabeled Factor VIIa or EDTA (final concentration 5 mM) upon the binding of '25I-Factor VIIa. It is evident from the figure, that a portion of the nonspecific binding (that present in an excess of unlabeled Factor VITa-see Methods) is calcium dependent. The reversal of binding by EDTA also indicates that endogenous Factor VII or VIla, which may have bound to the monocytes during their preparation, was removed during the subsequent EDTA washing steps employed before the use of the monocytes in these binding experiments. Fig. 6 Fig. 5 .
The Kd calculated from these kinetic data (Kd = K2/ K1) was 88 pM, very similar to that obtained by equilibrium binding.
When the equilibrium binding experiments were performed at 370C, however, double-reciprical evaluation of the data consistently revealed curvilinear plots (concave upwards) (Figs. 7 and 8 ). This nonlinearity prevented calculation of dissociation constants, but the apparent saturation binding was always severalfold greater than that noted when the same cells were incubated at 0°C. Intermediate results were obtained when the experiments were performed at 20°C. This effect is being investigated further (Discussion).
To determine if the binding of Factor VIIa to monocytes was associated with its ability to activate Factor X, two experiments were performed. In the first experiment, a direct relationship between the rate of Factor X activation in the reaction mixtures and the quantity of Factor VIla bound was demonstrated (Fig.  9 ). In the second experiment, the velocity of Factor CoC12 (mM) FIGURE 6 Dependence of '25I-Factor VIla binding upon calcium concentration. Mixtures containing 4 X 106/ml monocytes, 6 ng/ml '25I-Factor VIIa and varying concentrations of CaCl2 were incubated at 0°C. Duplicate mixtures containing additional unlabeled Factor VIla (final concentration 2.4 Ztg/ml) were used to determine nonspecific binding. After 60 min, specific binding was determined per 4 X 10' monocytes.
X activation in the whole reaction mixture (4 X 106/ ml monocytes, 6 ng/ml '251-Factor VIla, 4 mM CaCl2 at 20°C) was compared with the velocities obtained in supernatants of the mixture separated from the cells by centrifugation at 12,000 g for 2 min in a microfuge (as in the binding studies), or at high speed (105,000 g for 30 min). The rate of Factor X activation in the supernatant following microfuge centrifugation was 4% of that of the whole mixture. Essentially no Factor X activation could be detected in the 105,000 g supernatant of the same reaction mixture. The converting activity present in the 12,000 g X 2 min superna-
.0 - 10 20 30 [125I] FACTOR MEl OR MI. ADDED (ng/ml) FIGURE 7 Equilibrium binding of 1251-Factor VII and VIIa to monocytes. Binding was determined as described in Methods. Specific binding at 0°C per 4 X 106 monocytes is plotted vs. the concentration of 125I-Factor VII (0) or '25I-Factor VIla (0). Specific binding of 125I-Factor VIla at 37°C is also depicted (A). tant was apparently "particle" bound as it could be removed by a centrifugation speed commonly used to sediment membranes. Although this activity could represent active monocyte secretion or membrane shedding (27) , it appears as likely that it is related to mechanical manipulation of the monocytes during the in vitro incubation itself. The percentage of the total Factor Xa-converting activity, which remained in the microfuge supernatants, could be increased by raising the incubation temperature to 37°C, or by repeated, vigorous agitation of the mixtures. Competition between Factor VII and VIIa for their monocyte binding sites. To confirm that Factor VII and VIIa bind to the same monocyte sites, and with similar affinities, increasing concentrations of unlabeled Factor VII or Vlla were added to monocytes concomitantly with a constant amount of iodinated Factor VII or VIIa (final concentration 6 ng/ml). After a 1-h incubation at 0°C, the amount of bound radiolabeled protein was determined. As shown in Fig. 10 Before beginning the Factor VII and VIla binding studies reported here, a number of experiments were performed to determine the optimal conditions for tissue factor production in monocyte cultures (data not shown). In agreement with previous reports, our preliminary experiments showed that monocytes, but not lymphocytes, neutrophils, or platelets produced tissue factor activity following stimulation with LPS. In contrast to other studies (14, 15, 28, 29) , however, no dosedependent enhancement of monocyte tissue factor production was found when elutriator-purified lymphocytes were added to the monocyte cultures. As our monocyte preparations contained small numbers of lymphocytes (1-8%), no comment can be made upon the claim that lymphocytes are absolutely required for stimulation of monocyte tissue factor production (15, 30) . The addition of platelets to the monocyte cultures did enhance the amount of tissue factor activity produced (31) . This effect appeared to be substantial when a one-stage coagulation assay was used to determine tissue factor activity, but only modest (twofold in cultures containing 1 X 108 platelets and 5 X 105 monocytes per ml) when a more specific, two stage, chromogenic assay, using purified Factor VIIa and Factor X was used.3 Because the presence of platelets in the monocyte cultures made subsequent elution of the monocytes considerably more difficult, cultures of monocytes alone were used for the binding studies.
With the use of indirect functional assays, the apparent calcium-dependent binding of Factor VII to crude tissue factor preparations (5, 32) and a human monocytic tumor cell line (33) has been reported previously. In fact, radioactively labeled bovine Factor VII has been used as a probe to localize tissue factor in tissue slices (34) . Since the binding of Factor VIIa to the monocyte surface reported here was directly related to the velocity of subsequent Factor X activation, in all probability (essentially by definition), the Factor A number of proteases have been shown to activate Factor VII in purified, and in vitro plasma systems (38) (39) (40) (41) (42) . The kinetically most efficient of these appears to be Factor Xa, at least when purified reagents are used (38) . Whether this is also the case in vivo, and further, the extent of Factor VII activation that occurs in vivo, is not clear. It is of interest, however, that when plasma is induced to clot in vitro by small amounts of tissue factor, Factors IX and VIII are required for optimal Factor X activation and thrombin generation (43) (44) (45) . Along these same lines, the possible role of activated Factor VII as the Factor VIII bypassing activity in prothrombin complex concentrates has been suggested previously and is now being investigated further (46, 47) . 4 When the level of zymogen Factor VII is low, or the amount of Factor VII to Factor VIla decreased, one would expect the dampening effect of Factor VII to be diminished. It is tempting to speculate that the loss of this inhibitory effect of zymogen Factor VII might contribute to the thrombotic complications associated with congenital Factor VII deficiency (48) (49) (50) , loading dose coumarin therapy (51, 52) , and infusion of prothrombin complex concentrates, which may contain high levels of activated Factor VII (46, (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) .
